Lista de obras - Lucio Tentori - Dominio Público Uruguay

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib

artículo científico publicado en 2015

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

scientific article published on 19 September 2016

Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL)

scientific article published on 01 December 1995

Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.

artículo científico publicado en 2002

Challenging resistance mechanisms to therapies for metastatic melanoma.

artículo científico publicado en 2013

Chemopotentiation by PARP inhibitors in cancer therapy.

artículo científico publicado en 2005

Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.

artículo científico publicado en 2014

Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.

artículo científico publicado en 2001

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

artículo científico publicado en 2002

Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy

artículo científico publicado en 1988

Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine.

artículo científico publicado en 1997

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

artículo científico publicado en 2019

Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

artículo científico publicado en 2007

Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen.

artículo científico publicado en 1998

Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

artículo científico publicado en 2001

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth

artículo científico publicado en 2016

Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.

artículo científico publicado en 2009

Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.

artículo científico publicado en 2006

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid

scientific article published on 14 November 2018

Exploiting Microglial Functions for the Treatment of Glioblastoma.

artículo científico publicado en 2016

IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3′ dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro

article

In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds

artículo científico publicado en 1997

Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.

artículo científico publicado en 2013

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.

artículo científico publicado en 2008

Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

artículo científico publicado en 2006

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor

artículo científico publicado en 2003

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

artículo científico publicado en 2011

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

artículo científico publicado en 2013

Modulation of GDF11 expression and synaptic plasticity by age and training

artículo científico publicado en 2017

Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers

artículo científico publicado en 2014

N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.

artículo científico publicado en 2004

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma.

artículo científico publicado en 2015

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets

artículo científico publicado en 2013

Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells.

artículo científico publicado en 2009

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide

artículo científico publicado en 2014

Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.

artículo científico publicado en 2013

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide

artículo científico publicado en 2005

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

article

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

artículo científico publicado en 2002

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

artículo científico publicado en 2018

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

artículo científico publicado en 2002

Primary cultures of microglial cells for testing toxicity of anticancer drugs.

artículo científico publicado en 2004

Recent approaches to improve the antitumor efficacy of temozolomide.

artículo científico publicado en 2009

Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.

artículo científico publicado en 2005

Temozolomide reduces the metastatic potential of lewis lung carcinoma (3LL) in mice: Role of α-6 integrin phosphorylation

artículo científico publicado en 1995

The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.

artículo científico publicado en 2017

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

artículo científico publicado en 2017

The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.

artículo científico publicado en 2011

Thymic selection of the T-cell repertoire.

artículo científico publicado en 1988

Lista de obras de Lucio Tentori

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding

Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL)

Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.

Challenging resistance mechanisms to therapies for metastatic melanoma.

Chemopotentiation by PARP inhibitors in cancer therapy.

Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.

Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.

Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site

Comparative studies between in vitro and in vivo effects of human beta-interferon on natural killer activity and its relevance to immunochemotherapy

Cytokine-induced expression of CD1b molecules by peripheral blood monocytes: influence of 3'-azido-3'-deoxythymidine.

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes

Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

Effect of rifampin on CD1b expression and double-negative T cell responses against mycobacteria-derived glycolipid antigen.

Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components.

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth

Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.

Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid

Exploiting Microglial Functions for the Treatment of Glioblastoma.

IL-2 reverses the inhibition of cytotoxic T-cell responses induced by 5-(3,3′ dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) in vitro

In vitro antitumor activity of 3′-desamino-3′(2-methoxy-4-morpholinyl) doxorubicin on human melanoma cells sensitive or resistant to triazene compounds

Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.

Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Modulation of GDF11 expression and synaptic plasticity by age and training

Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers

N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.

Neuropilin-1 expressing melanoma cells as a model to study the aggressiveness of metastatic melanoma.

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets

Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells.

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide

Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis

Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.

Primary cultures of microglial cells for testing toxicity of anticancer drugs.

Recent approaches to improve the antitumor efficacy of temozolomide.

Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.

Temozolomide reduces the metastatic potential of lewis lung carcinoma (3LL) in mice: Role of α-6 integrin phosphorylation

The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells

The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.

Thymic selection of the T-cell repertoire.